Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anesthetic Effect - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Anesthetic Effect - Pipeline Review, H1 2016', provides an overview of the Anesthetic Effect pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect - The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects - The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anesthetic Effect Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Anesthetic Effect Overview 9 Therapeutics Development 10 Pipeline Products for Anesthetic Effect - Overview 10 Pipeline Products for Anesthetic Effect - Comparative Analysis 11 Anesthetic Effect - Therapeutics under Development by Companies 12 Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 14 Anesthetic Effect - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Anesthetic Effect - Products under Development by Companies 19 Anesthetic Effect - Products under Investigation by Universities/Institutes 20 Anesthetic Effect - Companies Involved in Therapeutics Development 21 Drawbridge Pharmaceuticals Pty Ltd 21 Jiangsu Hengrui Medicine Co., Ltd. 22 Juniper Pharmaceuticals, Inc. 23 Lipicard Technologies Limited 24 NanoMedex Pharmaceuticals, Inc. 25 Orbis Biosciences, Inc. 26 Paion AG 27 Phosphagenics Limited 28 Physica Pharma SAS 29 Primex Pharmaceuticals Oy 30 Proteus SA 31 Sphaera Pharma Pvt. Ltd. 32 Taiwan Liposome Company, Ltd. 33 The Medicines Company 34 Anesthetic Effect - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Combination Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 44 (oxymetazoline hydrochloride + tetracaine hydrochloride) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 ABP-700 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ADV-6209 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 alphaxalone - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 bupivacaine hydrochloride - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 bupivacaine hydrochloride ER - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 carboetomidate - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 gabafol - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 HSK-3486 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 lidocaine hydrochloride ER - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 LT-1121 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 LT-1123 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 methoxycarbonyl carboetomidate - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 methoxycarbonyl etomidate - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 neosaxitoxin - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PB-5109 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PHY-301 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 propofol - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 propofol microemulsion - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 propofol-DM - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 remimazolam - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 remimazolam - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Anesthetic Effect - Recent Pipeline Updates 76 Anesthetic Effect - Dormant Projects 82 Anesthetic Effect - Discontinued Products 84 Anesthetic Effect - Product Development Milestones 85 Featured News & Press Releases 85 Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy 85 Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings 85 Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting 86 Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 87 Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia 88 Jun 15, 2015: Juniper Pharmaceuticals Announces First Patient Enrolled in Phase II Study of COL-1077 as an Acute-Use Anesthetic for Minimally-Invasive Gynecologic Procedures 89 Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy 90 Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 90 Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion 91 Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 92 Appendix 93 Methodology 93 Coverage 93 Secondary Research 93 Primary Research 93 Expert Panel Validation 93 Contact Us 93 Disclaimer 94
List of Tables
Number of Products under Development for Anesthetic Effect, H1 2016 10 Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2016 21 Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 22 Anesthetic Effect - Pipeline by Juniper Pharmaceuticals, Inc., H1 2016 23 Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H1 2016 24 Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2016 25 Anesthetic Effect - Pipeline by Orbis Biosciences, Inc., H1 2016 26 Anesthetic Effect - Pipeline by Paion AG, H1 2016 27 Anesthetic Effect - Pipeline by Phosphagenics Limited, H1 2016 28 Anesthetic Effect - Pipeline by Physica Pharma SAS, H1 2016 29 Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H1 2016 30 Anesthetic Effect - Pipeline by Proteus SA, H1 2016 31 Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 32 Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 33 Anesthetic Effect - Pipeline by The Medicines Company, H1 2016 34 Assessment by Monotherapy Products, H1 2016 35 Assessment by Combination Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 43 Anesthetic Effect Therapeutics - Recent Pipeline Updates, H1 2016 76 Anesthetic Effect - Dormant Projects, H1 2016 82 Anesthetic Effect - Dormant Projects (Contd..1), H1 2016 83 Anesthetic Effect - Discontinued Products, H1 2016 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
